PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference

11 months ago

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of…

Humacyte’s Human Acellular Vessel™ (HAV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma

11 months ago

HAV granted second RMAT designation by the FDARMAT will support Humacyte’s lead indication in Vascular Trauma DURHAM, N.C., May 04,…

Outpace Bio, a Leader in Protein Design for Cell Therapy, Strengthens Executive Leadership Team with Key Appointments

11 months ago

Aaron Foster, Ph.D., Appointed to Chief Scientific Officer and Eric Soller, Ph.D., Appointed to Chief Business OfficerSeattle, WA, May 04,…

Teknova Announces Time Change for First Quarter 2023 Financial Results Conference Call on May 10, 2023

11 months ago

HOLLISTER, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents…

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

11 months ago

BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing…

Eargo to Report First Quarter 2023 Financial Results on May 11, 2023

11 months ago

SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission…

ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond

11 months ago

SEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases,…

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 months ago

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023…

BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update

11 months ago

- Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit…

SIGA Declares Special Cash Dividend of $0.45 Per Share

11 months ago

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced…